Search results for : erbb2 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: erbb2

Drugs (11)
Genetic Features (2)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
AZD8931	SN0216062465	EGFR, ERBB2, ERBB3	RTK signaling		GDSC1	913	SANGER
Afatinib	BIBW2992, Tovok, Gilotrif	EGFR, ERBB2	EGFR signaling	10184653	GDSC1	929	SANGER
Afatinib	BIBW2992, Tovok, Gilotrif	EGFR, ERBB2	EGFR signaling	10184653	GDSC1	903	SANGER
Afatinib	BIBW2992, Tovok, Gilotrif	EGFR, ERBB2	EGFR signaling	10184653	GDSC2	966	SANGER
CI-1033		EGFR, ERBB2, ERBB4	RTK signaling		GDSC1	916	MGH
CP724714	CP-724714	ERBB2	EGFR signaling	9874913	GDSC1	914	MGH
CUDC-101	CUDC 101	HDAC1-10, EGFR, ERBB2	Other	24756910	GDSC1	893	MGH
Lapatinib	Tykerb, Tyverb	EGFR, ERBB2	RTK signaling	208908	GDSC1	395	MGH
Lapatinib	Tykerb, Tyverb	EGFR, ERBB2	EGFR signaling	208908	GDSC2	966	SANGER
PF-00299804		EGFR, ERBB2, ERBB4	RTK signaling		GDSC1	909	MGH
Sapitinib	AZD8931	EGFR, ERBB2, ERBB3	EGFR signaling	11488320	GDSC2	966	SANGER

Feature Name	Feature Type
ERBB2IP_mut	coding variant
ERBB2_mut	coding variant

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).